Source-grounded facts extracted from LEMAITRE VASCULAR INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
LEMAITRE VASCULAR INC shareholders approved Ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for 2026 at the 2026-06-02 meeting.
“the stockholders ratified the selection of Grant Thornton LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 with a vote of 21,220,412 shares for and 108,474 shares against, with 7,415 shares abstaining.”
LEMAITRE VASCULAR INC shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-06-02 meeting.
“the stockholders approved, on an advisory basis, the Company's executive compensation by a vote of 19,311,813 shares for and 813,052 shares against, with 13,559 shares abstaining and 1,197,877 broker non-votes.”
LEMAITRE VASCULAR INC shareholders approved Election of two Class II directors at the 2026-06-02 meeting.
“David B. Roberts received a vote of 18,888,412 shares for, 1,250,012 shares withheld and 1,197,877 broker non-votes. John A. Roush received a vote of 14,229,071 shares for, 5,909,353 shares withheld and 1,197,877 broker non-votes.”
LEMAITRE VASCULAR INC reported Q2 2026 results: revenue $70.5mm - $72.5mm (Mid $71.5mm, +11%, +11% org.), EPS $0.79 - $0.84 (Mid $0.81, +35%.). Guidance raised.
“Business Outlook Q2 2026 Guidance Full Year Guidance Sales $70.5mm - $72.5mm (Mid $71.5mm, +11%, +11% org.) $277mm - $283mm (Mid $280mm, +12%, +12% org.) Gross Margin 72.1% 72.3% Op. Income $20.8mm - $22.3mm (Mid $21.6mm, +34%) $77.6mm - $82.0mm (Mid $79.8mm, +18%, +24% adj.) Op. Margin (Mid) 30% 29% EPS $0.79 - $0.84 (Mid $0.81, +35%.) $2.93 - $3.08 (Mid $3.00, +19%, +26% adj.)”
LEMAITRE VASCULAR INC reported Q1 2026 results: revenue Sales $66.6mm, EPS EPS $0.68.
“LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance. Q1 2026: • Sales $66.6mm, +11% (+10% organic) vs. Q1 2025 • Gross margin 72.7% (+350 bps) • Op. income $17.8mm (+41%) • Op. margin 27% • EPS $0.68 (+42%) • Cash up $8.1mm sequentially to $367.2mm”
Dorian LeBlanc was appointed as Chief Financial Officer at LEMAITRE VASCULAR INC.
“On February 7, 2025, LeMaitre Vascular, Inc. (the “Company”) agreed to terms with Dorian LeBlanc to become the Chief Financial Officer and principal financial officer of the Company, effective on March 10, 2025.”
Joseph P. Pellegrino, Jr. departed as Chief Financial Officer at LEMAITRE VASCULAR INC.
“On August 26, 2024, LeMaitre Vascular, Inc. (the “Company”), announced that Joseph P. Pellegrino, Jr. will retire as an employee of the company, including as Chief Financial Officer, effective as of March 7, 2025, following the anticipated filing of the 2024 Fiscal Year 10-K.”
LEMAITRE VASCULAR INC reported the quarter ended March 31, 2024 results: revenue $53.5mm, net income $9.9mm, EPS $0.44. Guidance reaffirmed.
“LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q1 2024 Financial Results ● Sales $53.5mm, +14% (+11% organic) vs. Q1 2023 ● Gross margin 68.6%, +300 bps ● Op. income $11.9mm, +51% ● Op. margin 22% ● Net income $9.9mm, +64% ● Earnings per diluted share $0.44, +62%”
LEMAITRE VASCULAR INC reported the quarter ended December 31, 2023 results: revenue $48.9mm, net income $8.5mm, EPS $0.38. Guidance initiated.
“of vascular devices, implants and services, today reported Q4 2023 results, announced a $0.16/share quarterly dividend and provided guidance. Q4 2023 Financial Results ● Sales $48.9mm, +19% (+14% organic) vs. Q4 2022 ● Gross margin 68.1%, +450 bps ● Op. income $10.2mm, +46% ● Op. margin 21% ● Net income $8.5mm, +50% ● Earnings per diluted share $0.38, +49% ●”
LEMAITRE VASCULAR INC reported quarter ended September 30, 2023 results: revenue $47.4mm, net income $7.5mm, EPS $0.33. Guidance initiated.
“of vascular devices, implants and services, today reported Q3 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q3 2023 Financial Results ● Sales $47.4mm, +21% (+16% organic) vs. Q3 2022 ● Gross margin 65.0%, +80 bps ● Op. income $9.2mm, +49% ● Op. margin 19% ● Net income $7.5mm, +38% ● Earnings per diluted share $0.33, +36% ●”
LEMAITRE VASCULAR INC amended Amendments (effective 2023-10-18).
“On October 18, 2023, LeMaitre Vascular, Inc. (the “Company”) entered into amendments (“Amendments”) to its leases for its headquarter properties located at 32-34 Third Avenue and 43, 53 and 63 Second Avenue in Burlington, Massachusetts.”
LEMAITRE VASCULAR INC reported the quarter ended June 30, 2023 results: revenue $50.1mm, net income $8.1mm, EPS $0.36. Guidance initiated.
“of vascular devices, implants and services, today reported Q2 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q2 2023 Financial Results ● Sales $50.1mm, +19% (+16% organic) vs. Q2 2022 ● Op. income $9.5mm, +63% (+8% adjusted) ● Op. margin 19% ● Net income $8.1mm, +130% (+27% adjusted) ● Earnings per diluted share $0.36, +127%”
LEMAITRE VASCULAR INC shareholders approved Ratification of the appointment of Grant Thornton LLP as independent registered public accounting firm for 2023 at the 2023-06-01 meeting.
“Proposal No. 3 – Ratification of the Selection of Independent Registered Public Accounting Firm By a majority of votes cast, the stockholders ratified the selection of Grant Thornton LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 with a vote of 20,105,297.71shares for and 92,675 shares against, with 3,262 shares abstaining.”
LEMAITRE VASCULAR INC shareholders approved Advisory vote on executive compensation at the 2023-06-01 meeting.
“Proposal No. 2 – Advisory Vote on Executive Compensation By a majority of votes cast, the stockholders approved, on an advisory basis, the Company's executive compensation by a vote of 18,603,555.38 shares for and 524,894 shares against, with 18,526.33 shares abstaining and 1,054,259 broker non-votes.”
LEMAITRE VASCULAR INC shareholders approved Election of two Class II directors at the 2023-06-01 meeting.
“Proposal No. 1 – Election of Directors By a majority of votes cast, the stockholders elected the following two nominees as Class II directors for a term of three years expiring upon the 2026 Annual Meeting of Stockholders or until their successor has been duly elected and qualified. Bridget A. Ross received a vote of 14,649,999.71 shares for, 4,496,976 shares withheld and 1,054,259 broker non-votes. John A. Roush received a vote of 18,526,479.71 shares for, 620,496 shares withheld and 1,054,259 broker non-votes.”
LEMAITRE VASCULAR INC reported Q1 2023 results: revenue $47.1mm, net income $6.0mm, EPS $0.27. Guidance initiated.
“devices, implants and services, today reported Q1 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q1 2023 Financial Results ● Sales $47.1mm, +19% (+22% organic) vs. Q1 2022 ● Op. income $7.9mm, -1% ● Op. margin 17% ● Net income $6.0mm, flat ● Earnings per diluted share $0.27, -1%”
LEMAITRE VASCULAR INC updated its the quarter ended March 31, 2023 guidance (initiated).
“On May 2, 2023, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended March 31, 2023.”
LEMAITRE VASCULAR INC reported the quarter ended December 31, 2022 results: revenue $41.0mm, net income $5.6mm, EPS $0.25. Guidance initiated.
“implants and services, today reported Q4 2022 results, announced a $0.14/share quarterly dividend (+12%) and provided guidance. Q4 2022 Financial Results ● Sales $41.0mm, +4% (+8% organic) vs. Q4 2021 ● Op. income $7.0mm, -16% ● Op. margin 17% ● Net income $5.6mm, -9% ● Earnings per diluted share $0.25, -9% ●”
Martha Shadan was appointed as director at LEMAITRE VASCULAR INC.
“the Board appointed Martha Shadan as a director of the Company effective as of such date”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.